Experience:
President, The Antibody Society
Advisor, Bioqube Ventures
Scientific Advisory Board member, Cartography Biosciences
Independent Biotech Consultant, Lust for Life Science B.V.
Senior Vice President, Genmab
Dr. Schuurman’s career centers around the antibody molecule as a biological source of inspiration and therapeutic modality. Dr. Schuurman joined Genmab’s R&D team in 2000 as one of the first scientists—her most recent position being Senior Vice President heading Genmab’s Antibody Research and Technologies. She is a co-inventor of many therapeutic antibodies and of the DuoBody®, HexaBody®, and HexElect® technologies, which enable the generation of bispecific and effector-function enhanced antibodies. These technologies are being applied to antibody therapeutic discovery programs at leading pharmaceutical and biotechnology companies worldwide and have resulted in FDA-approved therapies such as RYBREVANT® (amivantamab), EPKINLY® (epcoritamab), TECVAYLY® (teclistamab), and TALVEY® (talquatamab). Dr. Schuurman has championed many successful academic and industry partnerships in antibody therapeutics and complementary research fields.
Dr. Schuurman joined The Antibody Society’s Board of Directors in 2020 and currently serves as President of this international, non-profit trade association which represents individuals and organizations involved in antibody-related research and development. Dr. Schuurman is frequently invited to serve as a speaker, as well as a chair, at scientific conferences around the world due to her vision, impactful scientific publication track record, and dynamic presentations. She received her PhD in immunology from the University of Amsterdam. Dr. Schuurman is currently an independent biotech consultant (Lust for Life Science B.V.) and collaborates with many organizations, including Bioqube Ventures and Cartography Biosciences.
